
    
      A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour
      Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's
      Lymphoma.

      Primary

      • To assess the anti-tumour activity of Aplidin® given as a 1-hour weekly IV infusion, in
      patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy.

      Secondary

        -  To further investigate the safety profile of Aplidin® given as 1-hour weekly IV infusion
           in this patient population.

        -  To obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV
           infusion in patients with aggressive non-Hodgkin's Lymphoma.
    
  